128 related articles for article (PubMed ID: 19152185)
21. Genome-wide analysis for loss of heterozygosity in primary and recurrent phyllodes tumor and fibroadenoma of breast using single nucleotide polymorphism arrays.
Wang ZC; Buraimoh A; Iglehart JD; Richardson AL
Breast Cancer Res Treat; 2006 Jun; 97(3):301-9. PubMed ID: 16791486
[TBL] [Abstract][Full Text] [Related]
22. Breast Phyllodes Tumors Recruit and Repolarize Tumor-Associated Macrophages via Secreting CCL5 to Promote Malignant Progression, Which Can Be Inhibited by CCR5 Inhibition Therapy.
Nie Y; Huang H; Guo M; Chen J; Wu W; Li W; Xu X; Lin X; Fu W; Yao Y; Zheng F; Luo ML; Saw PE; Yao H; Song E; Hu H
Clin Cancer Res; 2019 Jul; 25(13):3873-3886. PubMed ID: 30890553
[TBL] [Abstract][Full Text] [Related]
23. MED12 mutations in breast phyllodes tumors: evidence of temporal tumoral heterogeneity and identification of associated critical signaling pathways.
Laé M; Gardrat S; Rondeau S; Richardot C; Caly M; Chemlali W; Vacher S; Couturier J; Mariani O; Terrier P; Bièche I
Oncotarget; 2016 Dec; 7(51):84428-84438. PubMed ID: 27806318
[TBL] [Abstract][Full Text] [Related]
24. Involvement of α- and β-catenins and E-cadherin in the development of mammary phyllodes tumours.
Tsang JY; Mendoza P; Lam CC; Yu AM; Putti TC; Karim RZ; Scolyer RA; Lee CS; Tan PH; Tse GM
Histopathology; 2012 Oct; 61(4):667-74. PubMed ID: 22571452
[TBL] [Abstract][Full Text] [Related]
25. Progressive deregulation of the cell cycle with higher tumor grade in the stroma of breast phyllodes tumors.
Kuijper A; de Vos RA; Lagendijk JH; van der Wall E; van Diest PJ
Am J Clin Pathol; 2005 May; 123(5):690-8. PubMed ID: 15981808
[TBL] [Abstract][Full Text] [Related]
26. Expression of EMT inducers integrin-linked kinase (ILK) and ZEB1 in phyllodes breast tumors is associated with aggressive phenotype.
Akrida I; Nikou S; Gyftopoulos K; Argentou M; Kounelis S; Zolota V; Bravou V; Papadaki H
Histol Histopathol; 2018 Sep; 33(9):937-949. PubMed ID: 29608014
[TBL] [Abstract][Full Text] [Related]
27. CD146 promotes malignant progression of breast phyllodes tumor through suppressing DCBLD2 degradation and activating the AKT pathway.
Chen J; Xu Q; Liu D; Li X; Guo M; Chen X; Liao J; Lei R; Li W; Huang H; Saw PE; Song E; Yan X; Nie Y
Cancer Commun (Lond); 2023 Nov; 43(11):1244-1266. PubMed ID: 37856423
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of epithelial-mesenchymal transition proteins Twist and Foxc2 in phyllodes tumours of the breast.
Lim JC; Koh VC; Tan JS; Tan WJ; Thike AA; Tan PH
Breast Cancer Res Treat; 2015 Feb; 150(1):19-29. PubMed ID: 25677742
[TBL] [Abstract][Full Text] [Related]
29. miR-21 induces myofibroblast differentiation and promotes the malignant progression of breast phyllodes tumors.
Gong C; Nie Y; Qu S; Liao JY; Cui X; Yao H; Zeng Y; Su F; Song E; Liu Q
Cancer Res; 2014 Aug; 74(16):4341-52. PubMed ID: 24980553
[TBL] [Abstract][Full Text] [Related]
30. Genetic analysis of uterine adenosarcomas and phyllodes tumors of the breast.
Geyer FC; Burke KA; Piscuoglio S; Ng CKY; Papanastasiou AD; Marchiò C; Selenica P; Edelweiss M; Murray MP; Brogi E; Soslow RA; Rubin BP; Norton L; Reis-Filho JS; Weigelt B
Mol Oncol; 2017 Aug; 11(8):913-926. PubMed ID: 28267263
[TBL] [Abstract][Full Text] [Related]
31. E-cadherin expression in the epithelial components of mammary phyllodes tumors.
Tsang JY; Mendoza P; Putti TC; Karim RZ; Scolyer RA; Lee CS; Pang AL; Tse GM
Hum Pathol; 2012 Dec; 43(12):2117-23. PubMed ID: 22820000
[TBL] [Abstract][Full Text] [Related]
32. Phyllodes tumor of the breast: an update.
Tse GM; Niu Y; Shi HJ
Breast Cancer; 2010; 17(1):29-34. PubMed ID: 19434472
[TBL] [Abstract][Full Text] [Related]
33. Hormonal receptors expression in epithelial cells of mammary phyllodes tumors correlates with pathologic grade of the tumor: a multicenter study of 143 cases.
Tse GM; Lee CS; Kung FY; Scolyer RA; Law BK; Lau TS; Putti TC
Am J Clin Pathol; 2002 Oct; 118(4):522-6. PubMed ID: 12375638
[TBL] [Abstract][Full Text] [Related]
34. In phyllodes tumors of the breast expression of SPARC (osteonectin/BM40) mRNA by in situ hybridization correlates with protein expression by immunohistochemistry and is associated with tumor progression.
Kim NI; Kim GE; Lee JS; Park MH
Virchows Arch; 2017 Jan; 470(1):91-98. PubMed ID: 27909812
[TBL] [Abstract][Full Text] [Related]
35. Expression of EMP1, EMP2, and EMP3 in breast phyllodes tumors.
Cha YJ; Koo JS
PLoS One; 2020; 15(8):e0238466. PubMed ID: 32857809
[TBL] [Abstract][Full Text] [Related]
36. Novel genetic aberrations in breast phyllodes tumours: comparison between prognostically distinct groups.
Tan WJ; Lai JC; Thike AA; Lim JC; Tan SY; Koh VC; Lim TH; Bay BH; Tan MH; Tan PH
Breast Cancer Res Treat; 2014 Jun; 145(3):635-45. PubMed ID: 24831776
[TBL] [Abstract][Full Text] [Related]
37. Stromal expression of vascular endothelial growth factor correlates with tumor grade and microvessel density in mammary phyllodes tumors: a multicenter study of 185 cases.
Tse GM; Lui PC; Lee CS; Kung FY; Scolyer RA; Law BK; Lau TS; Karim R; Putti TC
Hum Pathol; 2004 Sep; 35(9):1053-7. PubMed ID: 15343505
[TBL] [Abstract][Full Text] [Related]
38. p53 protein expression and gene mutation in phyllodes tumors of the breast.
Gatalica Z; Finkelstein S; Lucio E; Tawfik O; Palazzo J; Hightower B; Eyzaguirre E
Pathol Res Pract; 2001; 197(3):183-7. PubMed ID: 11314782
[TBL] [Abstract][Full Text] [Related]
39. Fibroepithelial lesions; The WHO spectrum.
Krings G; Bean GR; Chen YY
Semin Diagn Pathol; 2017 Sep; 34(5):438-452. PubMed ID: 28688536
[TBL] [Abstract][Full Text] [Related]
40. Loss of imprinting of IGF2 in fibroadenomas and phyllodes tumors of the breast.
Mishima C; Kagara N; Tanei T; Naoi Y; Shimoda M; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Oncol Rep; 2016 Mar; 35(3):1511-8. PubMed ID: 26676988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
